Interview with Ralf Dahmen, Managing Director, Galderma
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
Address: Level 1, 16 Napier Close DEAKIN ACT 2600,Australia
Tel: (602) 6282 6888
Web: http://www.pharmacouncil.com.au/
The Pharmaceuticals Industry Council is the peak body for Australia’s pharmaceutical and biotechnology industries. It brings together the innovative, generic and biotechnology industries to represent a whole-of-sector approach to addressing opportunities and threats to investment in the sector.
The PIC was established in June 2006, following the three-year implementation of the Government-endorsed Pharmaceuticals Industry Action Agenda. The PIC aims to take forward the work of the PIAA, particularly to double Australia’s share of the global pharmaceuticals industry by 2012.
The biopharmaceuticals sector in Australia employs approximately 34 000 people, exports almost $4 billion worth of medicines annually and invests more than $752 million per year in research and development collaborations with local hospitals, universities and research organisations. The industry is a major innovative contributor to the economy, and one of the most R&D intensive industries in Australia.
Investment, Intellectual Propery Rights, Corporate-Governmental relations
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
See our Cookie Privacy Policy Here
